Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies. Like many solid tumors, the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is shielded by the desmoplastic matrix-a dense barrier … Read more
Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research. The study, published in Scientific Reports, reflects a collaboration among scientists and oncologists in the United States, Australia, Qatar, and the United Arab Emirates … Read more
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials. Scientific Reports (2026). DOI: https://doi.org/10.1038/s41598-026-37464-4 Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of patients with multiple myeloma. SHARJAH, EMIRATE OF SHARJAH, UNITED ARAB EMIRATES, March 1, 2026 /EINPresswire.com/ — Commonly prescribed cardiovascular medications—such as … Read more
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions … Read more
TOPLINE: More than half (56.2%) of patients who are newly diagnosed with lymphoma and myeloma experience clinically significant anxiety or depression symptoms, with lower financial satisfaction and medical mistrust increasing anxiety risk. Depression symptoms, present in 27.5% of patients, were linked to significantly lower quality-of-life (QOL) scores. METHODOLOGY: A cross-sectional survey study conducted at Dana-Farber … Read more
A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled “NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma.” Researchers Andrea Gunnell, Scott T. Kimber, Richard Houlston, and Martin Kaiser from The Institute of Cancer Research, London, studied how a gene called NSD2 affects the behavior of multiple myeloma (MM) cells. … Read more
STUDIO CITY, Calif., March 13, 2025 (GLOBE NEWSWIRE) — The International Myeloma Foundation (IMF) is excited to announce that the 2nd annual Iceland Cycling Expedition (ICE)—a 6-night/7-day endurance fundraiser biking expedition —will take place from August 27 – September 2, 2025, in Reykjavik and through the highlands of Iceland to kick off Blood Cancer Awareness … Read more
Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become an essential part of the treatment of patients whose lymphoma or multiple myeloma has relapsed. This involves genetically modifying the patient’s own T lymphocytes (T cells) … Read more
New research shows that GD2 CAR-T cell therapy offers a potential cure for neuroblastoma, with some patients achieving long-term remission for over a decade—marking a major milestone in solid tumor treatment. Study: Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Image Credit: ART-ur / Shutterstock.com In a recent study published in Nature Medicine, … Read more